4.7 Article

Caffeic Acid Phenethyl Ester Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of Akt Signaling

Journal

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 14, Issue 5, Pages 8801-8817

Publisher

MDPI
DOI: 10.3390/ijms14058801

Keywords

oral cancer; caffeic acid phenethyl ester; TW2.6; cell proliferation; cell cycle; Akt; Akt1; Akt2; phospho-Akt Ser473; phospho-Akt Thr 308; FOXO1; FOXO3a; phospho-FOXO1 Thr24; phospho-FoxO3a Thr32; NF-kappa B; phospho-NF-kappa B Ser536; Rb; phospho-Rb Ser807/811; Skp2; cyclin D1; p27; 5-fluorouracil

Funding

  1. National Health Research Institutes, NHRI [CS-101-PP-14, CS-102-PP-14]
  2. National Science Council, NSC in Taiwan [NSC 99-2320-B-400-015-MY3, NSC 101-2325-B-400-014]
  3. Department of Health, DOH in Taiwan [DOH101-TD-C-111-004, DOH102-TD-C-111-004]
  4. Taiwan Tech Trek intern fellowship from Taiwan (NSC)
  5. protein chemistry Micro-Western Array core facility and cell sorter core facility of NHRI

Ask authors/readers for more resources

Caffeic acid phenethyl ester (CAPE) is a bioactive component extracted from honeybee hive propolis. Our observations indicated that CAPE treatment suppressed cell proliferation and colony formation of TW2.6 human oral squamous cell carcinoma (OSCC) cells dose-dependently. CAPE treatment decreased G1 phase cell population, increased G2/M phase cell population, and induced apoptosis in TW2.6 cells. Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3 beta, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kappa B, phospho-NF-kappa B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27(Kip). Overexpression of Akt1 or Akt2 in TW2.6 cells rescued growth inhibition caused by CAPE treatment. Co-treating TW2.6 cells with CAPE and 5-fluorouracil, a commonly used chemotherapeutic drug for oral cancers, exhibited additive cell proliferation inhibition. Our study suggested that administration of CAPE is a potential adjuvant therapy for patients with OSCC oral cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available